Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with alzheimer's disease: A randomized, double blind, placebo controlled withdrawal trial

Elio Scarpini, Giuseppe Bruno, Giuseppe Zappalà, Marina Adami, Ute Richarz, Maren Gaudig, Adam Jacobs, Barbara Schäuble

Research output: Contribution to journalArticlepeer-review

Abstract

Galantamine improved symptoms in Alzheimer's disease (AD) patients after 5 to 6 months of treatment. To examine long-term outcomes, this study assessed if continuing of galantamine treatment beyond 12 months delayed further cognitive deterioration. It consisted of two phases: an open label (OL) phase (12 months), followed by a double blind, randomized, placebo controlled withdrawal phase (up to 24 months). Subjects with mild to moderate AD were included in the study and titrated up to 16 mg/day of galantamine. Subjects were eligible to enter the double blind phase if a cognitive decline of

Original languageEnglish
Pages (from-to)211-220
Number of pages10
JournalJournal of Alzheimer's Disease
Volume26
Issue number2
DOIs
Publication statusPublished - 2011

Keywords

  • ADAS-cog
  • Alzheimer's disease therapy
  • cognitive
  • galantamine
  • long-term treatment
  • withdrawal design

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Fingerprint Dive into the research topics of 'Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with alzheimer's disease: A randomized, double blind, placebo controlled withdrawal trial'. Together they form a unique fingerprint.

Cite this